HDAC6 and endothelial dysfunction: HDAC6 expression and activity were upregulated in ox-LDL-treated ECs, which led to decreased expression of cystathionine γ-lyase and contributed to endothelial dysfunction (Leucker et al., 2017), and knockdown of HDAC6 or pharmacological inhibition with the dietary HDACi sodium butyrate (Hou et al., 2018; Wu et al., 2018), the inhibitor of Class I HDAC, could inhibit endothelial dysfunction.